These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27246397)

  • 1. Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.
    Uchida M; Saeki K; Maeda S; Tamahara S; Yonezawa T; Matsuki N
    J Vet Med Sci; 2016 Oct; 78(9):1515-1520. PubMed ID: 27246397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
    Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
    Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
    J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
    Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.
    Takada M; Parys M; Gregory-Bryson E; Vilar Saavedra P; Kiupel M; Yuzbasiyan-Gurkan V
    BMC Cancer; 2018 Mar; 18(1):237. PubMed ID: 29490634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum level of apoptosis inhibitor of macrophage in dogs with histiocytic sarcoma and its association with the disease.
    Uchida M; Matsumiya Y; Tsuboi M; Uchida K; Nakagawa T; Fujii W; Kobayashi T; Tsujimoto H; Ohmi A; Tomiyasu H; Motegi T; Maeda S; Momoi Y; Yonezawa T
    Vet Comp Oncol; 2023 Sep; 21(3):391-400. PubMed ID: 37088561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
    Yamazaki H; Takagi S; Hosoya K; Okumura M
    Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcoma.
    Kelly B; Thamm D; Rosengren RJ
    Vet Res Commun; 2024 Feb; 48(1):563-568. PubMed ID: 37597087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
    Yamazaki H; Takagi S; Hosoya K; Okumura M
    Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in Histiocytic Differentiation of Cell Lines From Canine Cerebral and Articular Histiocytic Sarcomas.
    Thongtharb A; Uchida K; Chambers JK; Nakayama H
    Vet Pathol; 2017 May; 54(3):395-404. PubMed ID: 28178429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
    Mason SL; Finotello R; Blackwood L
    Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases expression in spontaneous canine histiocytic sarcomas and its xenograft model.
    Fayyad A; Lapp S; Risha E; Pfankuche VM; Rohn K; Barthel Y; Schaudien D; Baumgärtner W; Puff C
    Vet Immunol Immunopathol; 2018 Apr; 198():54-64. PubMed ID: 29571518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
    Kisseberth WC; Murahari S; London CA; Kulp SK; Chen CS
    Am J Vet Res; 2008 Jul; 69(7):938-45. PubMed ID: 18593248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs.
    Kezer KA; Barber LG; Jennings SH
    Vet Comp Oncol; 2018 Mar; 16(1):77-80. PubMed ID: 28419676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
    Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
    J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
    Skorupski KA; Rodriguez CO; Krick EL; Clifford CA; Ward R; Kent MS
    Vet Comp Oncol; 2009 Jun; 7(2):139-44. PubMed ID: 19453368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
    Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
    Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA sequencing analysis and growth inhibitory effects of palbociclib on cell lines from canine histiocytic proliferative disorders.
    Hirabayashi M; Chambers JK; Tani A; Tomiyasu H; Motegi T; Rimpo K; Nakayama H; Uchida K
    Vet Comp Oncol; 2022 Sep; 20(3):587-601. PubMed ID: 35278028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
    Cannon C; Borgatti A; Henson M; Husbands B
    J Small Anim Pract; 2015 Jul; 56(7):425-9. PubMed ID: 25828786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma.
    Tani H; Kurita S; Miyamoto R; Sawada H; Fujiwara-Igarashi A; Michishita M; Azakami D; Hasegawa D; Tamura K; Bonkobara M
    J Am Anim Hosp Assoc; 2020; 56(3):146. PubMed ID: 32182105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.